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OBJECTIVE: Hyperhidrosis is a common disease, and thoracoscopic sympathectomy improves its symptoms in
up to 95% of cases. Unfortunately, after surgery, plantar hyperhidrosis may remain in 50% of patients, and
compensatory sweating may be observed in 70%. This clinical scenario remains a challenge. Our objective was
to evaluate the effectiveness of oxybutynin in the treatment of persistent plantar hyperhidrosis and
compensatory sweating and its effects on quality of life in women after thoracoscopic sympathectomy.
METHOD: We conducted a prospective, randomized study to compare the effects of oxybutynin at 10 mg daily
and placebo in women with persistent plantar hyperhidrosis. The assessment was performed using a quality-of-
life questionnaire for hyperhidrosis and sweating measurement with a device for quantifying transepidermal
water loss. Clinicaltrials.gov: NCT01328015.
RESULTS: Sixteen patients were included in each group (placebo and oxybutynin). There were no significant
differences between the groups prior to treatment. After oxybutynin treatment, there was a decrease in
symptoms and clinical improvement based on the quality-of-life questionnaire (before treatment, 40.4 vs. after
treatment, 17.5; p= 0.001). The placebo group showed modest improvement (p= 0.09). The outcomes of the
transepidermal water loss measurements in the placebo group showed no differences (p= 0.95), whereas the
oxybutynin group revealed a significant decrease (p= 0.001). The most common side effect was dry mouth
(100% in the oxybutynin group vs. 43.8% in the placebo group; p= 0.001).
CONCLUSION: Oxybutynin was effective in the treatment of persistent plantar hyperhidrosis, resulting in a
better quality of life in women who had undergone thoracoscopic sympathectomy.
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& INTRODUCTION
Hyperhidrosis is a relatively common disease, affecting
nearly 1 to 3% of the population (1,2). This condition is
characterized by excessive sweating in certain areas of
the body, particularly the hands, face, feet and armpits.
Thoracoscopic sympathectomy is effective for the treatment
of palmar, axillary and craniofacial sweating. This proce-
dure results in symptom improvement in 80% to 95% of
cases (3). However, compensatory sweating occurs as a side
effect, usually on the abdomen or back, in the majority of
patients (70%) (4-6).
In patients who also present with plantar hyperhidrosis,
foot sweating decreases after upper limb sympathectomy in
approximately 50% of cases, and the mechanisms involved
are not fully understood (7,8). This plantar sweating can be
relatively severe, often becoming as troublesome as the
original complaint, particularly in women who often wear
open shoes (9).
Plantar hyperhidrosis can be treated by laparoscopic
lumbar sympathectomy, but this invasive procedure risks
an increase in compensatory hyperhidrosis (10,11). Other
side effects can occur, such as vaginal dryness, retrograde
ejaculation, impotence, neuralgia and constipation (8,10).
Current assessment of hyperhidrosis is subjectively per-
formed using questionnaires. The generic SF-36 assessment
has been used; however, there is another questionnaire
specifically validated for assessing hyperhidrosis that
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focuses on palmar hyperhidrosis (12,13). Transepidermal
water loss (TEWL) can be measured as an objective
assessment, but there have been few studies published on
its use (14,15).
Because the sweat glands respond to cholinergic stimuli,
there is a rationale for using anticholinergic drugs; never-
theless, published data on the use of oxybutynin are limited
(16-19). A non-randomized, non-controlled study analyzed
the effect of oxybutynin as an initial treatment for plantar
hyperhidrosis, before thoracoscopic sympathectomy. The
drug yielded good results and improved quality of life
(QoL) (20). To the best of our knowledge, to date, there have
been no studies evaluating the use of oxybutynin for the
treatment of persistent hyperhidrosis in patients after
thoracic sympathectomy.
The objective of this study was to evaluate the effective-
ness of oxybutynin for the treatment of persistent plantar
hyperhidrosis in women who had undergone thoracic
sympathectomy.
& MATERIALS AND METHODS
This study was a prospective, randomized, double blind
clinical trial, with a control arm. Patient selection was
performed by telephone interview and/or by e-mail. The
selection criteria included female patients who had been
submitted to G3 and G4 thoracic sympathectomy for palmar-
plantar hyperhidrosis more than six months prior to the study.
The included patients had persistent plantar hyperhidrosis
that interfered with their usual activities. The exclusion criteria
were pregnancy, breastfeeding, glaucoma, use of tricyclic
drugs, BMI .25 Kg/m2 and previous use of anticholinergic
drugs. The patients were informed that oral dryness was a
more frequent side effect than other symptoms. The study
period was from March 2010 to June 2010.
The diagnosis of hyperhidrosis was based on each patient’s
clinical history, in addition to his or her social, emotional and
psychological characteristics. Therefore, the assessment after
treatment was performed subjectively, based on the patient’s
opinion and degree of satisfaction (20,21).
In this study, the subjective assessment was conducted
using a validated QoL questionnaire for hyperhidrosis with
scores ranging from 20 to 100 (13,14). This questionnaire
measures the negative impact of hyperhidrosis. The higher
the score is, the greater the impact on the patient’s QoL.
Given the 20- to 100-point variation in responses to the
questionnaire, we applied the mathematical formula below
to transform the score to a scale of 0 to 100, as in the SF-36,
which has also been used to evaluate hyperhidrosis (Table 1)
(12,22-24).
Formula for correction:
Measured value{Minimum valueð Þ
Difference between the limitsð Þ |100
Objective measurement of transpiration was performed
with a device for assessing TEWL by evaporation. This
‘‘Vapometer’’ (DefinH, Finland) is a battery-operated por-
table device with a humidity sensor in a closed chamber that
enables the measurement of evaporation on a 1-cm-diameter
patch of skin. The unit of measurement is grams (g) per
square meter (m2) per hour (h) and ranges from 0 to 300
g/m2/h (14,15). Hyperhidrosis was evaluated in the feet,
hands, back and abdomen.
The patients were randomized into two groups by
drawing lots, and they received oxybutynin or placebo
orally for 30 consecutive days. The patients were assessed
before and after the intervention. Oxybutynin was started at
2.5 mg daily and increased to a maximum of 10 mg to
prevent side effects (20).
During the statistical analysis, a power analysis showed
that the sample size required was 28 patients divided evenly
between the groups. The data for the analysis included the
following: TEWL in the left foot: 60.37 g/m2/h (8); standard
deviation (SD): 46.64 g/m2/h (8); number of controls per
case: 1; and expected response: reduction of at least 30%.
The necessary sample size was 14 patients per group. The
Wilcoxon test was performed to analyze the numeric
variables, and Fisher’s exact test was used to compare the
categorical variables. The significance level considered in all
statistical tests was 0.05.
This study was approved by the ethics committee of the
Federal University of Sa˜o Paulo (number 0609/08). This
clinical trial is registered at www.clinicaltrials.gov, number
NCT01328015.
& RESULTS
In total, 185 patients who had undergone sympathectomy
at the G3 and G4 levels for the treatment of palm-plantar
hyperhidrosis, more than six months prior to the study,
were evaluated. Among these patients, 78 (42%) had
persistent plantar hyperhidrosis, with discomfort in their
daily activities. In this study, 32 randomly selected patients
were enrolled and divided into two groups: oxybutynin and
placebo (Table 2). The groups were matched, and no
significant differences were found in any parameters before
treatment. The null hypothesis was retained by an analysis
of independent samples using the Mann Whitney U test,
with a significance level of 0.05.
Subjective assessment: The questionnaire results for QoL
are summarized in Table 3. In the placebo group, the
improvement did not reach statistical significance, in
contrast to the improvement in the oxybutynin group.
Objective assessment: TEWL showed a significant differ-
ence in the oxybutynin group and no changes after
treatment in the placebo group (Table 4).
Table 1 - Grades and values for the adjusted
questionnaire on quality of life.
Questionnaire
on quality of life
Adjusted questionnaire
on quality of life Grade
20-35 0-20 Excellent
36-51 21-40 Very Good
52-67 41-60 Good
68-83 61-80 Poor
84-100 81-100 Very Poor
Table 2 - Descriptive analysis of the groups: age, months
after sympathectomy and body mass index (mean and
standard deviation).
Group Age
Months after
sympathectomy
Body
mass index
Oxybutynin 25.5¡6.1 60.4¡31.9 21.3¡1.3
Placebo 28¡6.4 41.3¡30.1 22.4¡2.1
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The most common side effect was dry mouth, which was
present in all patients in the oxybutynin group and
approximately half of the patients in the placebo group
(43.8%; p= 0.001). The occurrence of other, less common
side effects, such as constipation and drowsiness, was not
significantly different between the groups (Table 5).
& DISCUSSION
The main goal of this study was to evaluate the
effectiveness of oxybutynin in the treatment of persistent
plantar hyperhidrosis and in the improvement of QoL in
women who had undergone previous thoracic sympathect-
omy. The study sample consisted of a random selection of
female patients presenting with disabling plantar hyperhi-
drosis after the operation.
A female target population was selected because of the
meaningfulness of their symptoms. Although both genders
experience compensatory sweating after sympathectomy,
males tend to complain more about abdominal and back
sweating. In contrast, females are more prone to being
bothered by foot sweating (4,5,21,24). Further studies should
be performed to evaluate such aspects and gender specifi-
cities.
We chose oxybutynin for the treatment of persistent
plantar hyperhidrosis because of this drug’s availability
and low cost. The drug exerts anticholinergic effects via the
muscarinic M3 receptor. Because the same receptor is
expressed in the salivary glands, the most common side
effect is dry mouth (3,9,16,18-20,25,26).
Oxybutynin has been widely studied for the management
of overactive bladder (27,28). The idea of using an oral
anticholinergic for the treatment of hyperhidrosis is not
original, as it was first reported in 1951 (17). There are
several clinical reports and case series on the use of
oxybutynin to treat plantar sweating, but to the best of
our knowledge, there have been no randomized clinical
trials on the subject so far (16,18-20,26,29-32).
We used one of the recommended QoL questionnaires for
hyperhidrosis (13). However, because its main focus is on
hand sweating, this questionnaire does not address plantar
hyperhidrosis, with only 2 of 20 questions asking about foot
sweating. Only 10% of the questions in this survey address
specific areas of the body other than the hands. Regarding
the hands, there are six direct questions (related writing,
performing crafts, holding objects, shaking hands, holding
hands and touching). Therefore, the questionnaire does not
adequately address either plantar hyperhidrosis or compen-
satory sweating. Such inadequate assessment may be the
reason why the results of the survey used in our study
showed a ‘‘good’’ or ‘‘very good’’ QoL despite the unequi-
vocal discomfort reported by patients.
Because sweat is primarily composed of water, it can be
measured based on TEWL (15,33). The device that we used
provides a promising method for the objective measurement
of sweat that has been used by cosmetics companies for
new-product research (33,34). Measurement of TEWL has
also been used to evaluate the therapeutic effect of botulin
toxin type A on palmar hyperhidrosis (14,33-36). The
method was sensitive because it managed to detect the
decrease in palmar sweating and the compensatory sweat-
ing on the back and abdomen (14,15,24,34). The possibility
of objective measurement for the evaluation of hyperhi-
drosis is promising, but unfortunately, the device is
expensive and not widely available.
Surprisingly, in this study, we found a high subjective
response in the placebo group. The ‘‘beneficial effect’’ of an
inert substance in a randomized clinical trial is expected to
be 35% on average, ranging from 10% to 60% (37). We
acknowledge that anxiety and stress can exacerbate sweat-
ing in people with either normal sweating or hyperhidrosis.
Such emotions might be mitigated by placebo. The present
study showed that the use of an antimuscarinic agent
yielded better results compared with placebo.
The presence of side effects differed between the groups.
Dry mouth was the most frequent, occurring in all patients
in the oxybutynin group and in 43.8% of patients in the
Table 3 - Oxybutynin and placebo groups - Means and standard deviations of the questionnaire results (measured and
corrected) before and after the intervention.
Treatment Before After p-value
Oxybutynin QoL HH 52.3¡11.5 ‘‘Good’’ 34.0¡9.5 ‘‘Excellent’’ 0.001*
A-QoL HH 40.4¡14.4 ‘‘Very Good’’ 17.5¡11.9 ‘‘Excellent’’ 0.001*
Placebo QoL HH 47.8¡13.0 ‘‘Very Good’’ 46.5¡12.2 ‘‘Very Good’’ 0.099
A-QoL HH 34.8¡16.3 ‘‘Very Good’’ 33.2¡15.3 ‘‘Very Good’’ 0.099
QoL: Quality-of-life questionnaire; HH: Hyperhidrosis; A: Adjusted.
Table 4 - Oxybutynin and placebo groups - Means and
standard deviations of the transepidermal water loss
measurements (g/m2/h) before and after the
intervention.
Treatment Before After p-value
Oxybutynin Temperature ( C˚) 24.4¡1.0 24.1¡1.0 0.157
R Ft (g/m2/h) 140.3¡40.3 87.6¡70.2 0.008*
R Hd (g/m2/h) 61.7¡43.9 28.6¡20.5 0.001*
Back (g/m2/h) 38.2¡64.3 10.8¡8.7 0.004*
Abdomen (g/m2/h) 39.7¡46.0 16.5¡19.2 0.00*4
Placebo Temperature ( C˚) 23.8¡1.2 23.9¡1.2 0.739
R Ft (g/m2/h) 112.6¡49.3 102.2¡55.9 0.796
R Hd (g/m2/h) 58.3¡39.3 50.4¡37.8 0.245
Back (g/m2/h) 18.2¡19.0 19.0¡27.9 0.959
Abdomen (g/m2/h) 24.0¡18.1 26.8¡31.4 0.501
R: Right; Ft: Foot; Hd: Hand; p: Wilcoxon test.
Table 5 - The presence of side effects in the placebo and
oxybutynin groups.
Side effects Placebo Oxybutynin p-value
Dry mouth 43.8% 100% 0.001*
Constipation 6.3% 31% 0.172
Drowsiness 6.3% 18% 0.6
Fisher’s exact test.
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placebo group. Two other studies on oxybutynin in
hyperhidrosis have reported dry mouth in 57% to 70% of
cases (16,18,20). When used for urinary incontinence,
oxybutynin causes dry mouth in 94% of patients (27,28).
Such an incidence of side effects can be lessened by the
use of transdermal oxybutynin (38) or other drugs, such
as darifenacin, solifenacin and fesoterodine (27,28).
Nevertheless, there are no studies on such promising drugs
in hyperhidrosis.
Despite the limitations of the present study, such as the
small sample size, the short follow-up and the limitations of
the questionnaire, our results demonstrate the potential
benefits of oxybutynin use in this clinical scenario.
In conclusion, this randomized clinical study showed that
oxybutynin was effective and safe for the treatment of
persistent plantar sweating in women who had undergone
thoracic sympathectomy. Further studies will be needed to
investigate new treatment regimens with this drug at lower
doses and to minimize the frequency and intensity of the
side effects.
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